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Burden of disease caused by Haemophilus inﬂ uenzae type b in 
children younger than 5 years: global estimates 
James P Watt, Lara J Wolfson, Katherine L O’Brien, Emily Henkle, Maria Deloria-Knoll, Natalie McCall, Ellen Lee, Orin S Levine, Rana Hajjeh, 
Kim Mulholland, Thomas Cherian, for the Hib and Pneumococcal Global Burden of Disease Study Team*
Summary
Background Haemophilus inﬂ uenzae type b (Hib) is a leading cause of childhood bacterial meningitis, pneumonia, and 
other serious infections. Hib disease can be almost completely eliminated through routine vaccination. We assessed 
the global burden of disease to help national policy makers and international donors set priorities.
Methods We did a comprehensive literature search of studies of Hib disease incidence, case-fatality ratios, age 
distribution, syndrome distribution, and eﬀ ect of Hib vaccine. We used vaccine trial data to estimate the proportion of 
pneumonia cases and pneumonia deaths caused by Hib. We applied these proportions to WHO country-speciﬁ c 
estimates of pneumonia cases and deaths to estimate Hib pneumonia burden. We used data from surveillance studies 
to develop estimates of incidence and mortality of Hib meningitis and serious non-pneumonia, non-meningitis 
disease. If available, high-quality data were used for national estimates of Hib meningitis and non-pneumonia, 
non-meningitis disease burden. Otherwise, estimates were based on data from other countries matched as closely as 
possible for geographic region and child mortality. Estimates were adjusted for HIV prevalence and access to care. 
Disease burden was estimated for the year 2000 in children younger than 5 years.
Findings We calculated that Hib caused about 8·13 million serious illnesses worldwide in 2000 (uncertainty range 
7·33–13·2 million). We estimated that Hib caused 371 000 deaths (247 000–527 000) in children aged 1–59 months, of 
which 8100 (5600–10 000) were in HIV-positive and 363 000 (242 000–517 000) in HIV-negative children.
Interpretation Global burden of Hib disease is substantial and almost entirely vaccine preventable. Expanded use of 
Hib vaccine could reduce childhood pneumonia and meningitis, and decrease child mortality.
Funding GAVI Alliance and the Vaccine Fund.
Introduction
Haemophilus inﬂ uenzae type b (Hib) is a common cause 
of serious diseases in children worldwide. Its most 
frequent manifestations are pneumonia and meningitis, 
but it can also cause infections of the epiglottis, soft 
tissues, bones, joints, and other sites.
Highly eﬀ ective and safe protein–polysaccharide 
conjugate Hib vaccines have been available for almost 
20 years. They have almost completely eliminated Hib 
disease in both developed and developing countries in 
which they are routinely used.1–7 These vaccines also 
reduce asymptomatic nasopharyngeal carriage and 
substantially protect unvaccinated people even at 
moderate vaccine coverage (40–50%).8–11 After licensure, 
Hib vaccines have been quickly introduced in North 
America and western Europe, but slowly in developing 
countries12 because of high cost, concerns about 
programme sustainability, limited vaccine supply, and 
uncertainty about Hib disease burden.13–15
Hib pneumonia is diﬃ  cult to identify, and surveillance 
studies underestimate the burden of other diseases caused 
by Hib.15–18 WHO has developed a rapid Hib disease 
assessment method that accounts for limitations of 
meningitis surveillance. The method also estimates the 
burden of Hib pneumonia on the basis of two clinical trials 
of Hib vaccine, which suggest that, for every case of Hib 
meningitis, there are ﬁ ve cases of radiographic Hib 
pneumonia.19–22 Vaccine trials to measure non-laboratory-
 conﬁ rmed Hib disease burden have provided important 
insights into the limitations of conventional surveillance 
studies and the burden of Hib disease.
WHO estimated that Hib causes about 3 million cases 
of serious disease and 386 000 child deaths every year.23 
The Bellagio Child Survival Study Group suggested that 
Hib vaccine could prevent 403 000 childhood deaths every 
year.24 We undertook this new analysis of the global 
burden of Hib disease for two reasons. The completion 
of two additional vaccine trials25,26 has helped to clarify the 
burden of Hib disease in Asian countries (where 
conventional methods showed low incidence of Hib 
meningitis) and provided data for the proportion of 
pneumonia preventable by Hib vaccines in Asia.15 We 
developed methods for country-speciﬁ c and regional 
estimates of Hib disease burden that are systematic and 
well documented. Our eﬀ ort was done together with a 
project to estimate the global burden of Streptococcus 
pneumoniae disease in children.27
Methods
Methods are described in detail in the accompanying 
webappendix pp 3–9, but a concise description is provided 
here. We did a literature review and developed methods for 
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estimating Hib disease burden from three serious clinical 
syndromes: meningitis, pneumonia, and non-pneumonia, 
non-meningitis invasive disease (disease in which Hib was 
isolated from a normally sterile body ﬂ uid). 
We did a literature review of studies published between 
1980 and 2005. We used broad search criteria to identify 
relevant studies from six global databases (Medline, 
Embase, CAB Health, Cochrane, Pascal, and Biosis) and 
four regional databases (African Index Medicus, Index 
Medicus for the WHO eastern Mediterranean region, 
Latin American and Caribbean Health Sciences 
Information, and Health Literature, Library and 
Information Services). Inclusion and exclusion criteria 
and quality assessments were applied to the studies 
identiﬁ ed. Literature review procedures are described 
elsewhere28 and in the webappendix pp 3,4.
According to WHO guidelines for release of 
country-speciﬁ c disease burden estimates, we undertook 
a country consultation process in 2007.29 An Independent 
Expert Panel reviewed twice, and advised on, the project 
methods. In response to these consultations, a small 
number of reports published in 2006–07 were included 
in the ﬁ nal analysis. These reports provided high-quality 
data based on the same quality assessment used for 
studies identiﬁ ed in the literature review from regions 
with scarce information.
Meningitis
We based our estimates of Hib meningitis incidence and 
case-fatality ratios on data from the literature review. 
Where country-speciﬁ c data were available, we used them 
to develop estimates for that country. If there were several 
estimates from a country, we generated a summary value 
using a random-eﬀ ects meta-analysis. When country-
 speciﬁ c data were not available, we developed estimates 
using data from epidemiologically similar countries. We 
hypothesised that reported Hib meningitis incidence and 
case-fatality ratios would correlate with child mortality and 
vary geographically. We deﬁ ned mortality strata of children 
younger than 5 years as low (<30 deaths in 1000 livebirths), 
medium (30–<75), high (75–<150), or very high (≥150). For 
countries without data, we used data from countries in the 
same child-mortality category. Geographic regions were 
deﬁ ned as the 21 UN subregions30 plus an African 
meningitis belt stratiﬁ cation. Estimates for countries 
without data were sought from other countries within the 
same subregion and mortality stratum. If no such data 
were available, the geographic area was hier archi cally 
expanded until data were available. If many studies were 
available within a given grouping, random-eﬀ ects 
meta-analysis was used to determine a summary estimate 
for countries in that grouping without data.
Most reported estimates of Hib meningitis incidence 
come from hospital-based surveillance studies. Some 
studies adjusted the incidence rates for case-ascer tain-
ment limitations or provided data from which 
adjustments could be made. Adjusted rates were used 
whenever available. Most estimates of Hib meningitis 
case-fatality ratios are from hospitalised case series. 
Because untreated Hib meningitis is fatal in most cases, 
case-fatality ratios for children without access to health 
care are likely to exceed those from studies in which 
treatment was provided. We adjusted the meningitis 
case-fatality ratios to account for access to health care. 
For the proportion of meningitis cases not reaching care, 
we assumed a 90% case-fatality ratio. We used the 
proportion of children younger than 5 years with 
suspected pneumonia in the past 2 weeks who were 
taken for care from the Multiple Indicator Cluster Surveys 
(MICS) as a proxy for the proportion of meningitis cases 
with access to care.31 For countries without MICS data, 
we applied regional MICS estimates. When those were 
unavailable, we used the third dose of diphtheria toxoid, 
tetanus toxoid, and pertussis vaccine (DTP3) coverage 
reported by WHO.32 For countries in Latin America 
where no other data were available, and for developed 
countries, we assumed 100% access to care.
We identiﬁ ed studies that quantiﬁ ed the relative risk 
for serious Hib disease associated with HIV infection 
and developed a summary risk ratio. We adjusted Hib 
meningitis incidence rates to account for diﬀ erences in 
HIV prevalence when data from other countries were 
used to develop estimates. We combined the estimated 
country-speciﬁ c Hib meningitis incidence and the 
number of children younger than 5 years to determine 
the number of Hib meningitis cases. We applied the 
country-speciﬁ c case-fatality ratio to calculate the number 
of Hib meningitis deaths.
Non-pneumonia, non-meningitis disease
We based our estimates for non-pneumonia, non-
meningitis disease burden on published series of 
conﬁ rmed, invasive Hib-disease cases that reported the 
anatomic site of disease. For each report, we calculated the 
ratio of non-pneumonia, non-meningitis disease to 
meningitis cases, and derived a mortality strata-speciﬁ c 
summary estimate of the ratio by combining relevant 
studies in a random-eﬀ ects meta-analysis. This ratio was 
applied to the country-speciﬁ c meningitis cases to estimate 
cases with non-pneumonia, non-meningitis disease. We 
used a similar approach to assess the case-fatality ratio of 
non-pneumonia, non-meningitis disease. The relation 
between mortality from Hib non-pneumonia, non-
meningitis disease and from Hib meningitis was 
determined from published studies, and a summary esti-
mate was generated from random-eﬀ ects meta-analysis. 
This estimate was applied to the country-speciﬁ c Hib 
meningitis case-fatality ratio to measure the case-fatality 
ratio for non-pneumonia, non-meningitis disease, which 
was then applied to the estimated non-pneumonia, 
non-meningitis disease cases to measure country-speciﬁ c 
Hib non-pneumonia, non-meningitis disease deaths. 
Adjustments for access to care and HIV prevalence were 
incorporated, as appropriate.
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Pneumonia
Because no sensitive and speciﬁ c tests for the diagnosis 
of Hib pneumonia are available, conventional sur-
veillance studies for Hib pneumonia are insuﬃ  cient 
and Hib pneumonia case-fatality ratios cannot be 
directly measured. Hib vaccine trials provide data, 
unrestricted by diagnostic test availability, for the 
proportion of pneumonia disease and deaths prevented 
by Hib vaccine.21 We identiﬁ ed studies that used a 
random or systematic allocation of Hib conjugate 
vaccine to measure a reduction in overall pneumonia 
incidence in vaccinated compared with unvaccinated 
children. This reduction in disease incidence is a 
function of both the proportion of disease caused by 
Hib and the eﬃ  cacy of the vaccine against Hib 
pneumonia. We have used vaccine eﬃ  cacy against 
invasive Hib disease to approximate the vaccine eﬃ  cacy 
against Hib pneumonia and to estimate the proportion 
of pneumonia caused by Hib for each study. Using 
random-eﬀ ects meta-analysis, we developed a summary 
estimate of the proportion of all-cause pneumonia cases 
caused by Hib. Owing to the small number of studies, a 
summary estimate was used for all countries and 
applied to country-speciﬁ c estimates of all-cause 
pneumonia cases.33 Adjustments for the increased risk 
of disease in HIV-positive children were incorporated.
A similar approach was taken to estimate deaths 
caused by Hib pneumonia. Although a reduction in 
pneumonia mortality is diﬃ  cult to measure 
experimentally, several studies have evaluated the 
diﬀ erence in incidence of pneumonia with radiographic 
consolidation between vaccinated and unvaccinated 
children. We assumed this diﬀ erence would be similar 
to the proportion reduction in all-cause pneumonia 
mortality associated with Hib vaccine use, and therefore 
the proportion of pneumonia deaths caused by Hib. 
Using a random-eﬀ ects meta-analysis, we combined 
estimates of the proportion reduction in pneumonia 
with radiographic consolidation from studies that used 
a random or systematic allocation of Hib-conjugate 
vaccine. We applied this proportion to WHO 
country-speciﬁ c estimates of all-cause pneumonia 
deaths in children aged 1–23 months to calculate the 
number of Hib-speciﬁ c pneumonia deaths by country.34 
Because clinical trials mainly included children younger 
than 2 years, we have no data for Hib pneumonia deaths 
in older children. Most serious Hib disease occurs 
before 2 years of age; therefore, we assumed no Hib 
pneumonia deaths after the second year of life. WHO 
estimates of all-cause pneumonia deaths do not include 
HIV-infected children. To estimate Hib pneumonia 
deaths in those children, we applied the derived 
country-speciﬁ c Hib pneumonia case-fatality ratio of 
HIV-negative children to the estimated number of cases 
of Hib pneumonia in HIV-positive children. All Hib 
disease burden estimates in HIV-infected children are 
reported separately. 
Uncertainty ranges
We report our estimates together with uncertainty ranges 
(UR; webappendix pp 5–7). The uncertainty bounds 
indicate the range of results generated by modifying the 
model structure or the literature estimates of disease 
incidence, and the statistical uncertainty.
Hib vaccine use
We estimated incidence rates in the absence of Hib 
vaccine. We then calculated cases and deaths for the year 
2000, accounting for direct and indirect protection from 
Hib vaccine and coverage for countries where vaccine 
was widely used. The number of serious Hib illnesses 
and deaths presented here, therefore, takes into account 
Hib-vaccine use in 2000. We also measured the number 
of serious illnesses and deaths prevented by Hib vaccine 
in children born in 2000, some of which would have 
occurred in subsequent years.
Reporting
Global and regional results are the sum of country-level 
results. Total values have been rounded and reported 
with three signiﬁ cant digits, and never more speciﬁ c 
than hundreds of cases or deaths. Country-speciﬁ c results 
are reported without rounding.
Role of the funding source
The sponsor had no role in the design, data collection, 
analysis, interpretation, or writing of the report. This work 
was done in collaboration with WHO, the PneumoADIP, 
and the Hib Initiative. The PneumoADIP and the Hib 
Initiative are funded by the GAVI Alliance and the Vaccine 
Fund. All authors had full access to the data and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We identiﬁ ed 15 099 studies by our literature search.35 
205 studies contributed data to Hib primary endpoints. 
For Hib meningitis, 110 studies provided incidence data, 
of which 59 met quality criteria; 116 provided age 
distribution data, and 50 reported data for case-fatality 
ratio. Data availability substantially varied in diﬀ erent 
regions (table 1). Of the 59 Hib meningitis incidence 
AFR AMR EMR EUR SEAR WPR Total
Meningitis incidence 10 (5) 12 (6) 5 (5) 16 (8) 3 (3) 13 (8) 59 (35)
Meningitis CFR 10 (8) 14 (8) 2 (2) 10 (6) 2 (2) 12 (7) 50 (33)
NPNM syndrome distribution 4 (2) 7 (6) 1 (1) 9 (7) 2 (2) 4 (3) 27 (21)
NPNM disease and 
meningitis CFR
0 (0) 1 (1) 0 (0) 2 (1) 0 (0) 2 (1) 5 (3)
Data are numbers of studies (countries). AFR=Africa. AMR=the Americas. EMR=eastern Mediterranean. EUR=Europe. 
SEAR=southeast Asia. WPR=western Paciﬁ c. CFR=case-fatality ratio. NPNM=non-pneumonia, non-meningitis. 
*Models grouped countries by UN subregions; therefore, this table does not fully reﬂ ect the number of countries, 
the model estimates of which were drawn from data within their region.
Table 1: Number of studies with Haemophilus inﬂ uenzae type b disease burden data that populated the 
meningitis and non-pneumonia, non-meningitis models*, by WHO region 
For more on country-speciﬁ c 
results see http://www.who.int/
immunization_monitoring/
burden/en/
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studies meeting quality criteria, only ﬁ ve were from the 
WHO eastern Mediterranean and three from southeast 
Asia region. By contrast, 16 were from Europe, 12 from 
the Americas, 13 from the western Paciﬁ c, and ten from 
Africa. Substantially fewer data were available for 
non-pneumonia, non-meningitis disease.35
We identiﬁ ed six studies that used Hib vaccine to 
measure the burden of Hib pneumonia; four met our 
inclusion criterion of having randomised or systematic 
vaccine distribution.21,22,25,26,36 We excluded two case-control 
studies37,38 done after routine Hib-vaccine introduction 
because access to vaccination might be independently 
associated with risk of Hib disease. Two studies from 
The Gambia21,36 and Indonesia25 provided data for the 
proportion of clinical pneumonia prevented by Hib 
vaccine, whereas all four studies showed data for the 
proportion of pneumonia with radiographic consolidation 
prevented by the vaccine. Figure 1 shows the eﬃ  cacy of 
Hib vaccine against diﬀ erent pneumonia endpoints for 
each study, the estimated proportion of each endpoint 
attributable to Hib, and the meta-analysis of the 
proportion of disease attributable to Hib.
We calculated that in 2000, Hib caused 8·13 million 
cases of pneumonia, meningitis, and invasive non-pneu-
mo nia, non-meningitis disease in children younger than 
5 years of age (uncertainty range [UR] 7·3–13·2 million). 
These cases resulted in an estimated 371 000 deaths in 
children 1–59 months of age, which includes 8100 deaths 
in HIV-positive children (table 2).
Southeast Asia had the largest numbers of cases and 
deaths, followed by Africa, the western Paciﬁ c, and the 
eastern Mediterranean. Widespread Hib vaccine use had 
a substantial eﬀ ect on the burden of Hib disease in the 
Americas and Europe. We estimated that, for children 
born in 2000, about 338 000 future Hib cases 
(304 000–542 000) and 12 500 future Hib deaths 
(8300–20 000) were averted by vaccination.
The estimated global incidence of Hib meningitis, in 
the absence of vaccination, was 31 cases per 
100 000 children younger than 5 years. Estimated 
incidence varied by region (table 2). Uncertainty ranges 
substantially overlapped across regions. Direct 
comparison between regions is complicated by 
diﬀ erences in methods and health-care services in the 
studies contributing to the estimates. In all regions, Hib 
meningitis was a severe disease with reported case-fatality 
ratios ranging from 22% to 67%.35
The estimated global incidence of Hib pneumonia, in 
the absence of vaccination, was 1304 per 100 000 children 
younger than 5 years (table 2). Because we developed a 
single global estimate for the proportion of Hib 
pneumonia cases, the main sources of regional variability 
in estimated Hib pneumonia incidence were the 
variability in all-cause pneumonia incidence and the 
prevalence of childhood HIV infection.
We identiﬁ ed only two studies with data for the 
proportion of clinical pneumonia prevented by Hib 
vaccine. One suggested that Hib vaccine prevented 7·7% 
of clinical pneumonia cases (95% CI –4·1% to 18·2%) 
in The Gambia, whereas the other estimated that Hib 
vaccine prevented 3·8% of such cases (–0·2% to 7·7%) 
in Indonesia.25,36 This proportion has a large eﬀ ect on 
our estimates. We identiﬁ ed four studies21,22,25,26,36 with 
data for the proportion of pneumonia with radiographic 
consoli dation prevented by Hib vaccine. Estimates from 
these studies varied substantially (ﬁ gure 1). The study 
from Indonesia25 found no reduction of pneumonia with 
radio graphic consolidation in vaccinated children. 
Without this study, the overall model estimate of the 
proportion of pneumonia with radiographic con-
solidation caused by Hib increases from 21% to 28%. By 
contrast, the case-control study from Bangladesh26 found 
Figure 1: Hib vaccine eﬃ  cacy
(A) Against clinical pneumonia. (B) Against pneumonia with radiographic consolidation. Error bars indicate 95% CI 
on the eﬃ  cacy estimates and the adjusted eﬃ  cacy estimates. *Adjusted for Hib vaccine eﬃ  cacy against invasive 
disease (a proxy for vaccine eﬃ  cacy against Hib pneumonia).
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that Hib vaccine prevented 32% of pneumonia with 
radiographic consolidation (95% CI 8–50%). Omission 
of this study results in a decrease in the overall model 
estimate from 21% to 15%. Thus, our uncertainty ranges 
for the contribution of Hib to pneumonia cases and 
deaths are wide.
To evaluate the stability of the meningitis disease 
burden estimate, we omitted each study individually 
Global Africa Americas Eastern 
Mediterranean
Europe Southeast Asia Western Paciﬁ c
Total
Deaths of 
children <5 years*
10 600 000
Children <5 years† 620 422 370 112 039 778 77 548 765 64 100 843 51 511 782 183 259 338 131 961 864
Incidence rate‡ 1342 (1210–2180) 1778 (1610–2877) 544 (488–875) 1417 (1284–2310) 304 (274–491) 1822 (1647–2969) 1142 (1017–1853)
Cases 8 130 000 
(7 330 000–13 200 000)
1 970 000 
(1 780 000–3 190 000)
286 000 
(257 000–463 000)
899 000 
(815 000–1 470 000)
129 000 
(116 000–209 000)
3 340 000 
(3 020 000–5 440 000)
1 500 000 
(1 340 000–2 440 000)
Death rate‡ 60 (40–85) 162 (112–224) 11 (7–15) 76 (52–110) 17 (11–24) 53 (33–77) 21 (12–31)
Total deaths 371 000 
(247 000–527 000)
181 000 
(126 000–251 000)
8400 (5200–11 700) 48 500 
(33 300–70 400)
8600 (5900–12 600) 97 200 (61 300–141 000) 27 200 (16 100–40 600)
Total deaths in 
HIV-positive
8100 (5600–10 000) 7800 (5400–9700) <100 (NA) <100 (NA) <100 (NA) <100 (NA) <100 (NA)
Total deaths in 
HIV-negative
363 000 
(242 000–517 000)
173 000 
(120 000–242 000)
8400 (5200–11 600) 48 400 
(33 300–70 300)
8600 (5900–12 600) 97 100 (61 200–140 000) 27 200 (16 100–40 600)
Pneumonia
Incidence rate‡ 1304 (1191–2131) 1724 (1574–2817) 510 (466–834) 1387 (1267–2267) 283 (259–463) 1790 (1635–2925) 1097 (1001–1792)
Cases 7 910 000 
(7 230 000–12 900 000)
1 910 000 
(1 740 000–3 120 000)
275 000 
(251 000–450 000)
880 000 
(804 000–1 440 000)
122 000 
(112 000–200 000)
3 280 000 
(3 000 000–5 360 000)
1 450 000 
(1 320 000–2 360 000)
CFR 4% (2–7%) 8% (5–14%) 1% (1–3%) 5% (3–9%) 5% (3–9%) 2% (1–4%) 1% (1–2%)
Death rate‡ 47 (33–69) 130 (92–189) 6 (4–9) 65 (46–95) 13 (9–18) 41 (29–60) 13 (9–19)
Deaths 292 000 
(206 000–425 000)
146 000 
(103 000–212 000)
4900 (3400–7100) 41 600 
(29 300–60 700)
6500 (4600–9500) 75 300 (53 000–109 900) 17 600 (12 400–25 600)
Deaths in 
HIV-positive
6400 (4500–8000) 6200 (4400–7800) <100 (NA) <100 (NA) <100 (NA) 100 (80–130) <100 (NA)
Deaths in 
HIV-negative
286 000 
(201 000–417 000)
140 000 
(99 000–205 000)
4900 (3400–7100) 41 500 
(29 200–60 600)
6500 (4600–9500) 75 200 (52 900–109 700) 17 600 (12 400–25 600)
Meningitis
Incidence rate‡ 31 (16–39) 46 (31–52) 25 (16–30) 24 (14–35) 16 (12–22) 27 (11–38) 34 (11–46)
Cases 173 000 
(85 300–226 000)
51 300 
(33 900–57 300)
8000 (4600–10 200) 15 400 
(9100–22 300)
5200 (3300–7300) 49 700 (19 600–68 800) 43 800 
(14 800–59 700)
CFR 43% (23–55%) 67% (44–75%) 28% (15–36%) 44% (26–62%) 27% (17–41%) 44% (17–62%) 22% (8–34%)
Death rate‡ 13 (7–16) 31 (20–35) 5 (2–6) 11 (6–15) 4 (3–6) 12 (5–17) 7 (3–11)
Deaths 78 300 
(41 600–101 600)
34 600 
(22 500–38 800)
3500 (1800–4600) 6800 (4000–9700) 2000 (1300–3100) 21 800 (8300–30 600) 9500 (3700–14 800)
Deaths in 
HIV-positive
1600 (1000–2000) 1600 (1000–1900) <100 (NA) <100 (NA) <100 (NA) <100 (NA) <100 (NA)
Deaths in 
HIV-negative
76 600 
(40 600–99 600)
33 000 
(21 500–36 900)
3500 (1800–4500) 6800 (4000–9600) 2000 (1300–3100) 21 800 (8300–30 600) 9500 (3700–14 800)
NPNM
Incidence rate‡ 7 (4–10) 8 (5–9) 9 (6–10) 5 (3–8) 5 (4–7) 5 (2–7) 11 (4–16)
Cases 39 600 (18 800–52 500) 8300 (5500–9300) 2600 (1600–3300) 320 (1800–4900) 1400 (1000–2100) 9100 (3900–12 500) 15 000 (5000–20 400)
CFR 1% (0–1%) 2% (1–2%) 1% (0–1%) 1% (1–1%) 1% (0–1%) 1% (0–1%) 1% (0–1%)
Death rate‡ 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Deaths 400 (200–500) 100 (80–140) <100 (NA) <100 (NA) <100 (NA) <100 (NA) <100 (NA)
Deaths in 
HIV-positive
<100 (NA) <100 (NA) <100 (NA) <100 (NA) <100 (NA) <100 (NA) <100 (NA)
Deaths in 
HIV-negative
400 (200–500) 100 (80–140) <100 (NA) <100 (NA) <100 (NA) <100 (NA) <100 (NA)
Data are estimates (uncertainty range). CFR=case-fatality rate. NPNM=non-pneumonia, non-meningitis disease. NA=not applicable. Uncertainty ranges not listed for fewer than 100 cases or deaths.  *Data from 
reference 28. †Data are from reference 30. ‡Per 100 000. 
Table 2: Haemophilus inﬂ uenzae type b cases and deaths, with uncertainty estimates, by syndrome and WHO region
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from the model to determine the individual contribution 
to the overall estimate. The estimated number of cases 
changed by more than 2% for only three studies, from 
Mongolia (18·9% decrease when omitted), Kenya (4·1% 
increase), and Indonesia (26·2% increase).5,25,39 Exclusion 
of data from Indonesia left no Asian studies in 
high-mortality strata, which necessitated the use of data 
from African high-mortality populations. The use of 
these data for Asian high-mortality settings resulted in 
increased estimated Hib meningitis incidence. The 
decrease in cases when the Mongolia study was omitted 
resulted from a higher reported incidence from Mongolia 
than from other Asian medium-mortality populations.
Discussion
We estimate that, in 2000, Hib caused 8·13 million 
serious illnesses (UR 7·33–13·2 million) and 
371 000 deaths (247 000–527 000) in children younger than 
5 years. Of the deaths, 8100 (5600–10 000) occurred in 
HIV-infected children. Hib disease accounted for 5·6% 
(3·9–7·7%) of the estimated 6·6 million post-neonatal 
child deaths and 16% of the estimated 1·8 million 
pneumonia deaths in HIV-negative children.28,40 These 
Hib-attributable deaths in children are almost entirely 
vaccine preventable. Our estimate of childhood mortality 
caused by Hib is consistent with previous estimates.23,24 
Because most deaths occurred in developing countries in 
Africa and Asia, Hib disease contributed to the disparity 
in child mortality between developed and developing 
countries (ﬁ gure 2). Just ten countries, all in Asia or 
Africa, account for an estimated 61% of childhood Hib 
deaths (ﬁ gure 3). These countries include those with 
high-mortality rates but small populations and those with 
moderate-mortality rates but large populations.
In 2000, the only regions with widespread use of Hib 
vaccine were Europe and the Americas. By 2006, however, 
108 countries—representing more than 55% of the 
world’s children—had implemented routine Hib 
vaccination.12 WHO and the GAVI Alliance, through their 
support for the Hib Initiative, have been working to 
expand supplies of Hib vaccine, reduce vaccine cost, and 
assist countries with vaccine introduction.12 Our data 
suggest that expanded use of Hib vaccines could 
considerably reduce child mortality worldwide.
Hib is also a major cause of child morbidity. We 
estimated that, in the absence of vaccination, 1·3% of 
children younger than 5 years (1·2–2·1%) would have an 
episode of Hib pneumonia each year—about 5·0% of 
cases of clinical pneumonia in 2000.33 Our estimate of 
Hib morbidity is substantially higher than previous 
estimates, mainly because we included Hib clinical 
pneumonia.
Our estimate of Hib meningitis disease burden is 
likely to be too low. Most Hib meningitis incidence 
studies we identiﬁ ed were surveillance studies, which 
systematically underestimate the burden of Hib disease. 
Trials to assess the eﬀ ect of Hib vaccine on clinical 
meningitis or culture-negative meningitis have shown 
that use of laboratory-conﬁ rmed disease alone 
substantially underestimates the burden of Hib 
Figure 2: Hib mortality rate
Hib deaths in children aged 1–59 months per 100 000 children (HIV-negative Hib deaths only). The boundaries shown and the designations used on this map do not 
imply the expression of any opinion by WHO concerning the legal status of any country, territory, city, or area, or of its authorities, or concerning the delimitation of 
its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
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meningitis, even with optimum laboratory facilities.25,26,41 
Hib non-pneumonia, non-meningitis disease burden is 
also likely to be underestimated because it is based on 
the meningitis disease burden estimates. Furthermore, 
most studies of invasive Hib disease we identiﬁ ed 
focused on meningitis. Data of the proportion of Hib 
non-pneumonia, non-meningitis diseases are scarce, 
and the proportion identiﬁ ed is likely to be under-
estimated by studies mainly focused on meningitis.
The paucity and variability of available data is reﬂ ected 
in our wide uncertainty ranges. These ranges are the 
results generated by modifying model structure, literature 
estimates of disease incidence, and statistical uncertainty 
of meningitis estimates. Our assumptions, if not valid, 
could increase the estimated uncertainty in unquantiﬁ able 
ways. We tried to assess the quality of study data and to 
include those studies with the most reliable results in 
our model. Only 29 of 110 studies (26%) of Hib meningitis 
incidence met our a-priori criteria for reliable results and 
almost all were done in developed countries.35 To 
encompass data from a wider range of countries, we 
included those studies judged to have reliable results by 
one of the two reviewers, resulting in a total of 59 studies 
for the meningitis incidence model. Almost half of the 
identiﬁ ed studies were excluded because both reviewers 
identiﬁ ed data-quality limitations. The large number of 
Hib meningitis incidence studies with unreliable results 
has contributed to uncertainty about Hib disease 
burden in many countries. Better standardisation and 
reporting of methods and limitations for surveillance 
studies are needed.17
We considered diﬀ erent approaches to estimate the 
burden of Hib pneumonia (webappendix pp 4,5). 
Because no sensitive and speciﬁ c diagnostic tests for 
Hib pneumonia exist, few data for Hib pneumonia 
burden are available. Our use of results from Hib 
vaccine probe studies to determine the incidence of 
vaccine-preventable pneumonia has drawbacks. The 
incidence of vaccine-preventable disease is a function of 
total incidence and vaccine eﬃ  cacy. The eﬃ  cacy of Hib 
vaccine against Hib pneumonia is not known. We have 
used the eﬃ  cacy of Hib vaccine against invasive Hib 
disease as a proxy, but it is likely that this eﬃ  cacy against 
Hib pneumonia is lower, leading to a bias towards 
underestimating Hib pneumonia incidence and disease 
burden. Only two studies of Hib vaccine eﬀ ect on clinical 
pneumonia met our inclusion criteria.21,25,36 The 
proportion of clinical pneumonia caused by Hib is 
crucial for our estimate of Hib cases. The small number 
of studies and substantial variability between them led 
to wide uncertainty bounds around these estimates. 
Additionally, the case-detection method for clinical 
pneumonia cases diﬀ ered between vaccine trials and 
all-cause pneumonia incidence studies. If the 
contribution of Hib to clinical pneumonia cases 
identiﬁ ed in the incidence studies is less than in vaccine 
trials, we might have overestimated Hib pneumonia 
cases. This would not aﬀ ect the Hib pneumonia 
mortality estimates.
Similarly, only four vaccine probe studies21,22,25,26,36 had 
data for pneumonia with radiographic consolidation, 
which we used in our Hib pneumonia death model. The 
study methods and deﬁ nition for radiographic con-
solidation were not standardised across these studies: 
two were randomised clinical trials with a-priori 
pneumonia endpoints;25,36 one was a case-control trial 
with systematic vaccine allocation;26 and one was a 
post-hoc analysis of a Hib-vaccine trial.22 Diﬀ erences in 
methods and results in these studies make comparisons 
diﬃ  cult and lead to uncertainty in our estimates of Hib 
pneumonia mortality. Estimates of Hib pneumonia 
deaths are highly sensitive to the estimate of all-cause 
pneumonia deaths. Uncertainty in this estimate 
contributes to uncertainty in our results (webappen dix 
p 5).42,43 A single estimate of the proportion of pneumonia 
with radiographic consolidation due to Hib was applied 
globally. The contribution of Hib might, however, vary 
by region. The Hib pneumonia case-fatality ratio is likely 
to be lower in settings with ready access to health care 
than where access is limited. Our model assumes that 
the Hib pneumonia case-fatality ratio is the same as for 
all other pneumonia causes, so we might have 
overestimated the burden of Hib pneumonia deaths in 
settings with ready access to care and underestimated it 
in settings with limited access. Because most Hib 
pneumonia deaths are in settings with limited access to 
health care, our model probably underestimates the 
global burden of Hib pneumonia deaths.
Vaccine studies on which our Hib pneumonia estimates 
are based focused on children younger than 2 years, and 
the number of Hib pneumonia cases and deaths in 
children older than 2 years is not known. For Hib 
meningitis, we found that the proportion of cases in 
children aged 2–4 years was 4–18%, depending on 
Figure 3: Ten countries with the greatest number of Hib deaths*
HIV infected and uninfected. Bubble size indicates the number of Hib deaths. *Country (number of deaths): 
India (72 000), Nigeria (34 000), Ethiopia (24 000), Democratic Republic of the Congo (22 000), China (19 000), 
Afghanistan (14 000), Pakistan (13 000), Bangladesh (12 000), Angola (9000), and Niger (8000).
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childhood mortality (data not shown). Thus, some Hib 
pneumonia cases and deaths probably also occur in 
children older than 2 years. However, in the absence of 
vaccine trial data for Hib pneumonia in children older 
than 2 years, we assumed that there were no Hib 
pneumonia deaths in this age group, and consequently 
we might have underestimated Hib pneumonia deaths. 
Because data are available, our estimates of Hib 
meningitis and non-pneumonia, non-meningitis diseases 
deaths include children aged 2–4 years. Furthermore, our 
estimates are subject to general methodological 
limitations (webappendix pp 3–9). 
Our methods for estimating the burden of Hib 
pneumonia and Hib meningitis diﬀ ered substantially. 
The overall ratio of Hib pneumonia to meningitis cases 
based on these two diﬀ erent approaches was 46:1, 
substantially higher than the 5:1 ratio estimated by 
previous studies.21,22 There are several possible 
explanations for this ﬁ nding. The 5:1 ratio was based on 
pneumonia with radiographic consolidation, whereas 
our estimates are of Hib-attributable clinical pneumonia. 
Studies upon which the 5:1 ratio is based might have 
underestimated the pneumonia incidence because of 
incomplete case ascertainment, resulting in an 
underestimation of the pneumonia-to-meningitis ratio.21 
Also, we might have underestimated Hib meningitis 
burden or overestimated the burden of Hib clinical 
pneumonia, as described above.
Our study identiﬁ ed several important limitations in 
data availability. Additional high-quality Hib-disease-
 burden studies could narrow the uncertainty ranges and 
result in disease estimates that are higher or lower than 
those provided here. However, such studies, especially 
vaccine probe studies, are expensive, time consuming, and 
ethically questionable since WHO has recommended 
inclusion of Hib vaccines in all routine immunisation 
programmes without waiting for local disease-burden 
data.23 Furthermore, Hib vaccines are increasingly available, 
prices are declining, and vaccine ﬁ nancing through the 
GAVI Alliance is available for low-income countries.12 
Doubts might remain about the true burden of Hib disease, 
especially in parts of Asia, but their importance decreases 
as vaccine availability increases and prices fall. Studies in 
developing countries that have introduced Hib vaccine 
with GAVI support should help resolve many issues 
regarding disease burden and vaccine eﬀ ect.
Widespread implementation of safe and eﬀ ective Hib 
vaccines could reduce mortality of children younger than 
5 years. We hope that these estimates will assist national 
and international policy makers in their assessments of 
the value of prevention of Hib disease.
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